Reference pricing with evidence development: a way forward for proton therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.International journal of environmental research and public health · 2020
   Pooled it
2. Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee.International journal of radiation oncology, biology, physics · 2021
   Review
3. Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices.Journal of the National Cancer Institute · 2020
   Review
4. Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care.Prostate cancer and prostatic diseases · 2019
   Review
5. Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol.BMJ open · 2019
   Article
6. Patient Prioritization for Proton Beam Therapy in a Cost-neutral Payer Environment: Use of the Clinical Benefit Score for Resource Allocation.Cureus · 2019
   Article
7. Insurance Approval for Proton Beam Therapy and its Impact on Delays in Treatment.International journal of radiation oncology, biology, physics · 2019
   Article
8. Randomized Trials of Proton Therapy: Why They Are at Risk, Proposed Solutions, and Implications for Evaluating Advanced Technologies to Diagnose and Treat Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
   Article
9. Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances.Journal of thoracic disease · 2018
   Review
10. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Article
11. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop.International journal of radiation oncology, biology, physics · 2017
    Article
12. A 20-Year Analysis of Clinical Trials Involving Proton Beam Therapy.International journal of particle therapy · 2017
    Article
13. [Progress on the Therapeutic Approaches for Malignant Tumor 
with Superior Vena Cava Syndrome].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2016
    Review
14. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome.SpringerPlus · 2016
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as